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Lapatinib and Sorafenib Kill GBM Tumor Cells in a Greater than Additive
Manner
By Mehrad Tavallai
Major Director: Paul Dent, Ph.D.
Department of Biochemistry

Abstract
Glioblastoma multiforme (GBM) is the most common and malignant brain tumor
in adults, affecting thousands of people worldwide every year, with a life expectancy,
post diagnosis of 12 months. Surgery, radiotherapy and chemotherapy together, result in
an overall mean survival not exceeding 15 months. Targeted therapeutic agents sorafenib,
an oral multi kinase inhibitor, and lapatinib, an epidermal growth factor receptor (EGFR)
inhibitor, used in combination have been shown to kill GBM cells be through inhibition
of major growth mediating signaling pathways that are frequently over expressed in
gliomas, including mitogen-activated protein kinase (MAPK) and phosphatidylinositol 3kinase/ protein kinase B (PI3K/AKT). Sorafenib can restore lapatinib induced
cytotoxicity by down regulation of myeloid cell leukaemia-1 (Mcl-1) expression. Prior
studies have shown Mcl-1 to play an important role in resistance to lapatinib.
Furthermore, data indicated that this drug combination is able to trigger activation of
autophagic and apoptotic pathways and induce endoplasmic reticulum (ER) stress
response in GBM cells, collectively resulting in cell death. In conclusion, data presented
here demonstrates that the combination of sorafenib and lapatinib can kill GBM cells in a
greater than additive fashion, through induction of autophagy, apoptotic events (extrinsic
and intrinsic) and ER stress.
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Introduction

Glioblastoma Multiforme
Glioblastoma multiforme (GBM) is the most common and lethal primary
malignant brain tumor in adults.18,54,64 Its prognosis remains dismal since the majority of
glioblastomas develop very rapidly without any clinical evidence with the median
survival time not exceeding 15 months, even with the available therapies.18,54,63,64 In the
United States, about 20,000 people are diagnosed with GBM annually and the number of
patients diagnosed with this aggressive malignancy is increasing globally.63 The main
reasons for the lethality of glioblastomas include the highly invasive nature of tumor
cells, the resistance of these cells to chemotherapeutics in the brain micro-environment
and the existence of blood-brain barrier, which makes it difficult for therapeutic agents to
reach and remain in the brain tissue adequately.57 Therefore, there is an urgent need for
new therapies which can fight this fatal disease more effectively. The advent of molecular
targeted therapies was a turning point in the battle against cancer, and these novel
molecular inhibitors have been subject to many in vitro and in vivo studies ever since.
Currently, there are several targeted agents in clinical trial for the treatment of patients
with GBM as individual agents or in combination with radiation and chemotherapy and
their efficacy is yet to be determined.18 These therapeutic agents are selected based upon
their capacity to modulate the signal transduction pathways that are commonly
dysregulated in GBM cells such as mitogen-activated protein kinase (MAPK) and
phosphatidylinositol 3-kinase (PI3K) which result in abnormal cellular growth and
proliferation.58,64 Table 1 provides the names and characteristics of four GBM cell lines
used in this study.
11

Cell Line

Characteristics

GBM5

Over expresses PDGFRα, Mutant PI3K

GBM6

Mutant Variant - EGFR vIII

GBM12

Expresses mutant active full length EGFR

GBM14

Mutant PTEN

Table 1. The list of GBM cells used in the study and their mutational characteristics.

Conventional Therapy
The conventional therapy for patients with GBM include surgical removal of
tumor to the extent feasible, followed by adjuvant high-dose radiotherapy and
chemotherapy.18,54 Currently, the common chemotherapeutic used in this treatment is
temozolomide (TMZ), an oral alkylating agent. TMZ induces the formation of O6methylguanine in DNA, which mispairs with thymine during the next cycle of DNA
replication resulting in double strand breaks and eventually activation of apoptotic
pathways.5,20 The previous studies have shown that the median survival time of patients
receiving radiotherapy and TMZ concomitantly was 14.6 months as compared to 12.1
months with radiotherapy alone.54 Unfortunately, this clinically meaningful survival
benefit is overshadowed by the harsh toxicity and devastating side effects in GBM
patients. The limited success of TMZ is mainly due to chemoresistance and the inability
of TMZ to induce apoptosis.5 The ability of alkylating agents to induce apoptosis depends
upon O6-methylguanine-DNA methyltransferase (MGMT) activity and the activity of
various survival pathways.5 MGMT is an important DNA repair enzyme, and methylation
of its promoter has been shown to extend the median survival time of GBM patients who
received concurrent radiotherapy and TMZ by 6.4 months.20 Tumor tissue samples from
12

patients receiving TMZ treatment indicated that AKT and Extracellular Signal-Regulated
Kinase (ERK)1/2 were phosporylated.5 In a similar study, Hirose et al 21 showed that
activation of AKT protects GBM cells from TMZ-induced cytotoxicity. Moreover, it was
reported that the chemo resistance of GBM cells to TMZ was partially diminished with
inhibitors of PI3K/AKT and ERK1/2/ MAP kinase pathways.5 Collectively, the findings
presented here elucidate the significance of these cellular survival pathways in GBM cells
and suggest that they can potentially serve as targets for future therapeutic treatment.

Targeted Therapy
Typically, conventional chemotherapy does not discriminate between rapidly
dividing normal cells and cancer cells, has low therapeutic efficacy and often produces
palliative and unpredictable responses. In contrast, targeted therapies only interfere with
molecular targets within tumor cells, have a high specificity and cause less toxicity.3
Therefore, targeted therapy represents a more promising approach based upon the
molecular understanding of tumorigenesis, which may potentially replace conventional
cytotoxic chemotherapy in the near future. A major setback to this novel therapy is the
potential for crosstalk between cellular survival pathways. This may result in the cell
activating an alternative survival pathway in the event of blockade of a specific pathway;
thus, leading to drug resistance. For instance, recent clinical trials revealed that EGFR
tyrosine kinase inhibitors, used as single agents, are of little therapeutic benefit in patients
with GBM, which commonly possess deregulated EGFR signaling pathway.58 Therefore,
there is growing evidence that the use of targeted therapeutics in combination provides a
more rational strategy to increase the efficacy of treatment.
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There are multiple types of targeted therapeutics available, including monoclonal
antibodies, antisense inhibitors of growth factor receptors, and most importantly,
inhibitors of tyrosine kinases.3 The two targeted therapeutics used in this study, sorafenib,
a multi serine/threonine/tyrosine kinase inhibitor, and lapatinib, an inhibitor of EGFR
tyrosine kinase, will be introduced in the following section.

Sorafenib
Sorafenib (BAY 43-9006, Nexavar) is an oral multi kinase inhibitor, which was
primarily designed to inhibit Raf kinase, a serine/threonine kinase, but was shown to have
an inhibitory effect on mutant Raf and a variety of tyrosine kinases including vascular
endothelial growth factor receptor (VEGFR) 2/3, platelet-derived growth factor receptorβ (PDGFRβ), FLT3, Ret, and c-Kit with half maximal inhibitory concentrations (IC50) in
the nanomolar ranges.24,30,40,41,53,61 The development cycle of sorafenib took
approximately 11 years and it was approved by Food and Drug Administration (FDA) in
December 2005 for the treatment of advanced renal cell carcinoma (RCC).60

Figure 1. Chemical structure of sorafenib tosylate.24
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Crystallographic analyses of sorafenib interaction with the kinase domain of BRaf revealed that the inhibitor bound to the ATP-binding pocket, thus inhibiting substrate
binding and phosphorylation.42
In vivo and in vitro studies have indicated the ability of sorafenib to inhibit tumor
growth and tumor microvasculature through anti-proliferative, anti-angiogenic, and proapoptotic effects.61 Recent studies concerned with the mechanism of action of sorafenib
have shown the induction of cell death through a process involving induction of ER stress
leading to down-regulation of anti-apoptotic protein, Mcl-1.40,41
Sorafenib toxicity has been well tolerated by patients who received up to 800
milligrams (mg) of the drug per day and the side effects have been limited to fatigue,
diarrhea and hand or foot skin reactions.50,52

Lapatinib
Lapatinib (GW-572016, Tykerb) is a tyrosine kinase inhibitor which inhibits
EGFR/ErbB-1 and Her-2/ErbB-2 signaling, with IC50 values of 10.2 and 9.8 nanomolar
respectively.6,32,58,62 In January 2010, lapatinib was granted accelerated FDA approval to
be used in combination with letrozole for the treatment of hormone receptor positive
metastatic breast cancer that over-express ErbB-2 receptor.32,56 Lapatinib exhibits
reversible, non-covalent inhibition of EGFR and ErbB-2 by binding in the ATP-binding
cleft located on the intracellular kinase domain of these receptors; thus leading to
inactivation of downstream signal proteins.32,62 Computational studies have shown that
binding of lapatinib to the ATP binding pocket of EGFR receptors perturbs their three
dimensional structure and results in accumulation of inactive EGFR dimmers on the cell
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surface. These inactive dimers serve as ligand traps, since they are able to bind the
growth factor molecules without receptor phosphorylation at the kinase domain.46
Although EGFR is amplified or mutated in nearly half of GBM cells, molecular
inhibitors of this receptor have not yielded high efficacy in clinical trials, indicating the
existence of resistance mechanisms.7 Consequently, a phase I/II clinical study of lapatinib
in recurrent GBM failed to produce any appreciable benefit.58 Resistance to EGFR
inhibitors occurs mainly through secondary mutations in the receptors, through activation
of alternative tyrosine kinase pathways, or through over-expression of anti-apoptotic
proteins, specifically Mcl-1.8,34 Recent studies have demonstrated that lapatinib resistance
is mediated by elevated expression of Mcl-1 and not by secondary mutation of EGFR
receptors.32-34
Lapatinib caused minimal toxic effects in patients who received up to 1500 mg of
the drug per day with the adverse events being limited to diarrhea, rash, nausea, and
fatigue.6

Figure 2. Chemical structure of lapatinib.26
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Epidermal Growth Factor Receptor Tyrosine Kinase
The EGFR/ErbB family is a critical component in the autocrine growth regulation
of carcinoma, and is comprised of four different receptors; EGFR/ErbB1, ErbB2/HER2,
ErbB3/HER3, and ErbB4/HER4.47 All of these trans-membrane proteins are within the
170-190 kilo Dalton (kDa) size range and are composed of three different domains; the
extracellular ligand-binding domain, hydrophobic trans-membrane domain, and
intracellular catalytic domain.27,47 The hydrophobic domain anchors the receptor in the
membrane and connects the cysteine-rich growth factor binding extracellular domain to
the intracellular tyrosine kinase catalytic domain.47 Unlike ErbB1, 2 and 4 which are
catalytically active, ErbB3 does not have an active tyrosine kinase domain, but remains
competent for ligand binding and signal transduction.62 Ligand binding or receptor overexpression induces homo- or hetero-dimerization of ErbB receptors, which results in
trans-phosphorylation of tyrosine residues located on the intracellular catalytic domain.47
The phospho-tyrosine residues on the cytoplasmic side of the receptor act as docking
sites for Src homology 2 (SH2) domain-containing signaling proteins that are involved in
activation of multiple downstream metabolic signaling cascades including PI3K/AKT
and Ras/Raf/MAPK.17,38,47
EGFR is amplified in approximately 40-50% and over-expressed in more than
60% of glioblastomas. Nearly 40% of the GBMs with EGFR amplification possess a
constitutively active mutant form of the receptor, EGFRvIII.36,38 This mutation leads to
deletion of exons 2-7 of the EGFR gene, which makes the receptor incapable of binding
to any known ligand.16 It has been shown that EGFRvIII plays a significant role in
chemo-resistance, most notably by activating PI3K/AKT signaling pathway and its
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downstream targets such as mammalian target of rapamycin (mTOR).16 As a result, new
approaches to the treatment of recurrent GBM mostly include combinations of targeted
therapeutics that can inhibit both EGFRs and their downstream signaling cascades
simultaneously.36

Mitogen-Activated Protein Kinase Pathway (MAPK)
MAPK pathways are evolutionary conserved signaling cascades that transduce
extracellular signals to the fundamental intracellular processes such as growth,
proliferation, migration and apoptosis.11 MAPK pathways consist of a three-tier kinase
module in which a downstream MAPK is activated upon phosphorylation by MAPK
kinase (MAPKK), which in turn is activated when phosphorylated by its upstream
MAPK kinase kinase (MAPKKK).11,42 There are four major, well characterized
mammalian MAPK kinase pathways that activate four distinct terminal serine/threonine
kinases, ERK1/2, c-Jun amino-terminal kinase (JNK), p38 kinase and ERK5 (Figure 3).42
While ERK1/2 is normally activated by growth factors, JNK, p38 and ERK 5 usually
become activated in response to environmental stress such as osmotic shock and ionizing
radiation.11,42 Recently, two more mammalian MAPK pathways have been discovered
that lead to activation of ERK3/4 and ERK 7/8 while the rest of the components of these
pathways are currently unknown.11 Among all, the ERK1/2 MAPK signaling pathway,
commonly deregulated in GBM, has drawn a great deal of attention due to its pivotal role
in vital cell functions including growth, differentiation, survival migration and
angiogenesis, and has grown as a major target for cancer drug discovery.11,39
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Figure 3. Four major mammalian MAPK pathways.42 MAPK pathways are comprised
of three-tier kinase module in which a MAPKKK phosphorylates the downstream
MAPKK, which in turn phosphorylates its downstream serine/threonine MAPK. Among
the MAPKs activated by these four pathways, only ERK1/2 responds to growth factors.
ERK5, JNK and p38 are mainly activated due to environmental stress such as osmotic
shock and ionizing radiation.
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Ras/Raf/MAPK Pathway
When growth factors bind to their receptors, they induce dimerization and autophosphorylation of tyrosine residues on the catalytic domains of these receptors. These
phospho-tyrosines act as docking sites for growth factor receptor-bound protein 2
(GRB2), an adaptor protein, and sons of sevenless (SOS), an exchange factor, which
together result in the activation of Ras (Figure 4).25
Ras GTPases act as molecular switches that mediate activation of many signaling
pathways.11 Inactive guanosine diphosphate (GDP)-bound Ras activity is regulated by
guanine nucleotide exchange factors (GEFs), such as SOS, which promote the formation
of active guanosine triphosphate (GTP)-bound Ras, whereas GTPase-activating proteins
(GAPs), such as neurofibromin 1 (NF1), induce GTP hydrolysis and formation of
inactive GDP-bound Ras.11,42 Activated GTP-bound Ras then recruits Raf from the
cytosol to the cell membrane where a multi step activation process occurs.25 Although
Ras is commonly mutated in a variety of cancers, mutations in Ras have rarely been
reported in GBM.39
Raf serine/threonine kinases are direct effectors of Ras and work at the apex of
this pathway. There are different mutant forms of Raf whose structures are similar, but
differ considerably in their modes of regulation, tissue distribution, and the ability to
activate MAPK/ERK kinase (MEK).11 Raf-1 is expressed in all tissues, whereas A-Raf is
predominantly found in urogenital tissue and B-Raf in neural tissue and testis.25 All three
isoforms are able to phosphorylate MEK with B-Raf being the strongest activator and ARaf the weakest.25 Both wild type B-Raf and constitutively active mutant B-Raf V600E,
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that is overexpressed in 15-20% of high-grade pediatric gliomas, are inhibited by
sorafenib.10,42,60
Activated Raf then phosphorylates MEK1/2 at two serine residues located on the
kinase domain, which in turn binds to and phosphorylates ERK1/2. Activated ERK1/2
can translocate to the nucleus and induce genetic responses that regulate processes such
as proliferation, differentiation, survival, migration and angiogenesis.11,25

PI3K/AKT Pathway
When growth factors bind to the membrane receptor tyrosine kinases including
EGFR, PDGFR and Insulin-like growth factor 1 receptor (IGFR), they induce receptor
phosphorylation and membrane recruitment of PI3K.9,45 PI3K is a lipid kinase that is
comprised of two separate subunits, a regulatory p85 and a catalytic p110, which
heterodimerize upon activation.9,29 Activated PI3K phosphorylates the lipid
phosphatidylinositol 4,5-biphosphate (PIP2) generating the second messenger
phosphatidylinositol 3,4,5-triphosphate (PIP3).9,29,45 PIP3 in turn recruits both
phosphatidylinositol-dependent kinase 1 (PDK1) and AKT to the membrane, where AKT
becomes phosphorylated by PDK1 and mTORC2/rapamycin-insensitive companion of
mTOR(Rictor) to become fully active (Figure 5).9,45 Activated serine/threonine AKT
induces several different cellular responses, such as protein synthesis, survival, migration
and apoptosis through phosphorylation of multiple downstream effectors.4 Among all of
the AKT targets, mTOR has a critical role as a nutrient sensor and is generally
deregulated in a variety of cancers including GBM.9,45 Activated mTOR phosphorylates
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Figure 4. Ras/Raf/MAPK signaling pathway. Upon ligand binding, the tyrosine
residues on the kinase domain of EGFRs become transphosphorylated, which act as
docking sites for the adaptor protein GRB2. SOS binds to GRB2 and activates Ras by
exchanging GDP for GTP. GTP-bound Ras recruits Raf from cytosol to the membrane
and activates it, which in turn activates MEK1/2 by phosphorylating two distinct serine
residues. Activated MEK1/2 then phosphorylates ERK1/2 that translocates in the nucleus
and induces multiple cellular responses.
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p70S6 kinase (p70S6K) and eukaryotic initiation factor 4E (eIF4E)-inhibitory binding
protein (4EBP) resulting in activation of p70S6K and eIF4E and increase in protein
synthesis consequently.9,45
The PI3K/AKT pathway is negatively regulated by phosphatase and tensin
homolog (PTEN), a lipid phosphatase that dephosphorylates PIP3 to PIP2.4,9,45 Mutations
of PTEN occurs in 15-40% of GBM, and results in constitutive activation of AKT
pathway and cannot be compensated for by any other tumor suppressor.45

Apoptosis: Intrinsic and Extrinsic Pathways
Apoptosis, also referred to as programmed cell death type I (PCDI), is an energydependent multi-step biochemical process that plays a crucial role in tissue homeostasis
in multicellular organisms, and its deregulation contributes to many diseases, including
cancer, autoimmunity and AIDS. Morphologically, apoptosis is characterized by
membrane blebbing, cell shrinkage, nucleus fragmentation, chromatin condensation and
DNA degradation.13,48,51 There are two distinct apoptotic pathways: the extrinsic or death
receptor pathway and the intrinsic or mitochondrial pathway. However, new evidence
suggested that these two pathways are connected and the components of one pathway can
influence the other.13 Both extrinsic and intrinsic pathways converge on the activation of
specific intracellular poteases, the caspase family. Caspases are intracellular cysteine
proteases that cleave proteins next to aspartate residues. Caspases, typically categorized
into initiators and executioners, are synthesized as inactive zymogens and become
activated upon cleavage by their upstream modulators.13,65 Caspase 3 is the most
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Figure 5. PI3K/AKT signaling pathway. The lipid kinase PI3K binds the kinase
domain of the EGFR receptor, and phosphorylates PIP2 to generate PIP3, a second
messenger. PIP3 recruits both PDK1 and AKT to the membrane where PDK1
phosphorylates AKT. Activated AKT induces protein synthesis and survival through
interaction with various substrates. mTOR, a major AKT target that acts as a nutrient
sensor, phosphorylates p70S6K and 4EBP. Released eIF4E and phospho-p70S6K
translocate to the nucleus and induce protein synthesis. This pathway is negatively
regulated by phosphatase PTEN, which dephosphorylates PIP3 to PIP2.
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important of the executioner caspases, and is activated by any of the initiator caspase 8, 9
and 10 in both extrinsic and intrinsic pathways. Executioner caspases (caspase 3, 6 and 7)
cleave various substrates including cytoskeletal and nuclear proteins, and also activate
other proteases and endonucleases involved in protein degradation and DNA
fragmentation.13,65
Unlike the extrinsic pathway that is mediated by death receptors, the intrinsic
pathway is strictly controlled by the B-cell lymphoma-2 (Bcl-2) family of proteins.13,65
The Bcl-2 family consists of three different classes: the anti-apoptotic group I, the proapoptotic group II and group III proteins that bind and regulate the activity of antiapoptotic group II proteins. Group I family members such as Bcl-2, Bcl-x long (Bcl-xL)
and myeloid cell leukaemia-1 (Mcl-1) directly bind and inhibit pro-apoptotic group II
family members including Bcl-2-associated X protein (Bax) and Bcl-2 homologous
antagonist/killer (Bak). Whereas, the group III family members including p53
unregulated modulator of apoptosis (Puma), NADPH oxidase activator (Noxa), BH3
interacting domain death agonist (BID) and Bcl-2 interacting mediator of cell death
(BIM) interact with pro-apoptotic group II family members and induce their insertion in
the mitochondrial membrane.13,48,65 Recent studies have demonstrated a role for the tumor
suppressor p53 in synthesis of Puma and Noxa, linking DNA damage to apoptotic cell
death.37,66
The intrinsic pathway is activated by various stimuli such as viral infection, DNA
damage and absence of certain growth factors, hormones and cytokines. After exposure
to these stimuli, Bax and Bak are inserted in the outer membrane of mitochondria leading
to mitochondrial membrane permeabilization, formation of pores, and release of
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cytochrome-c and other pro-apoptotic proteins, such as caspase-activated
deoxyribonuclease (CAD), apoptosis-inducing factor (AIF) and endonuclease G, from the
inter-membrane space into the cytosol.13,65 In the cytosol, cytochrome-c binds apoptotic
protease-activating factor-1 (Apaf-1), which in turn binds pro-caspase 9 to form a
complex known as the apoptosome. Binding to Apaf-1 induces conformational change
and activation of caspase 9, which proteolytically activates executioner caspase 3.13,65
Besides its proteolytic activity in the cytosol, cleaved caspase 3 can also activate caspase
6, another executioner caspase, and CAD by cleaving its inhibitor (ICAD). CAD
alongside AIF and endonuclease G, which unlike CAD function in a caspase-independent
manner, translocate to the nucleus where they lead to DNA fragmentation.13,51,65
The extrinsic signaling pathway is activated when death receptors bind their
natural ligands from the tumor necrosis factor (TNF) family. These death receptors,
which belong to the TNF receptor family, consist of a cysteine-rich extracellular domain
for ligand binding and a cytoplasmic domain of 80 amino acids called the death domain
(DD) involved in signal transduction.13,48,51 The best-characterized member of this family
is Fas receptor, also known as cluster of differentiation 95 (CD95). The Fas receptor is a
45-kDa trans-membrane protein that binds to its ligand (FasL) through its cysteine-rich
extracellular domain. Ligand binding induces conformational changes in the receptor
structure that allows Fas to recruit an adaptor protein called Fas-associated death domain
(FADD). FADD contains another important motif, the death-effector domain (DED) that
binds initiator caspases 8 and 10 through complementary DED domains.13,48,51 This
death-inducing signaling complex (DISC) leads to auto-proteolytic cleavage and
activation of caspases 8 and 10, which subsequently activate executioner caspases 3 and 7
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to induce apoptotic response (Figure 6).13,48,51 The extrinsic pathway may also result in
the release of cytochrome-c and the induction of the intrinsic pathway through activation
of BID that serves as a substrate for caspase 8. Upon activation at the DISC, truncated
BID (tBID) translocates to the mitochondria and induces the release of apoptotic proteins
from the intermembrane space into the cytosol.13,28,48 The extrinsic apoptotic pathway is
regulated at early stage by FLICE-inhibitory proteins (FLIP), which bind to the DISC and
inhibit activation of caspase 8.48,51

Autophagy
Autophagy is an evolutionary conserved degradative mechanism that is required
for maintaining cellular homeostasis by recycling and turnover of cytoplasmic
components. Autophagy is associated with various physiological and pathological
processes including development, aging, cancer, neurodegenerative disorders and
infectious diseases.2,31,55 Cancer therapeutics also have the ability to induce autophagy
predominantly through interruption of EGFR pathway, activation of MAPK signaling
pathways and induction of ER stress.2
Autophagy occurs in three different modes: macroautophagy, microautophagy
and chaperone-mediated autophagy. Macroautophagy (hereafter referred to as autophagy)
is the main lysosomal rout for recycling long-lived macromolecules and also organelles,
such as mitochondria and peroxisomes, when damaged or in excess. It is characterized by
formation of double-membrane vesicles named autophagosomes around targeted cellular
components, which directly fuse with lysosomes for enzymatic degradation.
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Figure 6. Intrinsic and extrinsic apoptotic pathways.19 The intrinsic pathway is
controlled by Bcl-2 family of proteins that induce release of cytochrome c from the
intermembrane space of mitochondria into the cytosol. Cytochrome c causes Apaf-1 to
bind and activate initiator caspase 9. Cleaved caspase 9 then activates executioner
caspase 3. On the other hand, the extrinsic pathway is initiated by binding of TNFs to the
TNFRs. The TNFRs then recruit adaptor protein that can bind and activate initiator
caspases 8 and 10. These initiator caspases in turn activate caspases 3 and 7. Caspase 8
can also activate BID, which can translocate to the mitochondria and induce release of
cytochrome c.
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Microautophagy involves direct engulfment of cytoplasmic components into the
lysosome through invagination of the lysosomal membrane, whereas chaperone-mediated
autophagy is the selective degradation of cytoplasmic proteins, which contain a specific
motif that can be recognized by lysosomal receptors.2,31,55
Out of 31 autophagy-related genes (ATG) discovered by yeast genetic studies, 18
genes are involved in autophagosome formation. Since autophagy is an evolutionary
conserved process, most of these genes have mammalian homologs with similar
functionality.23,31,55
Mammalian ATG9 is a trans-membrane protein essential for autophagosome
formation that has localizes to the trans-Golgi Network (TGN). Upon starvation, Baxinteracting factor-1 (Bif-1) co-localizes with ATG9 and induces fragmentation of Golgi.
The ATG9-containing fragments are dispersed in the cytosol and are utilized for
autophagosome formation.55 This process requires activation of class III PI3K (PI3KC3)
complex, which consists of PI3KC3, p150, Beclin-1, ultraviolet radiation resistanceassociated gene (UVRAG) and ATG14L that acts upstream of ATG9 trafficking. PI3KC3
forms a complex with p150 adaptor that tethers the enzyme to the cytoplasmic
membrane. PI3KC3 then binds Beclin-1 that serves as a binding partner for UVRAG and
ATG14L. Bif-1 binds the complex by interacting with UVRAG. Activation of PI3KC3
complex II is regulated by mTOR signaling and is crucial for ATG9 trafficking and
initiation of autophagosome formation.23,31,43,55 Nutrient deprivation inhibits mTOR
inhibitory effect on Unc51-like kinase 1 (ULK1). Activated ULK1 is recruited by
ATG14L to directly phosphorylate Beclin-1 and induce activation of PI3KC3. Activated
PI3KC3 phosphorylates phosphatidylinositol (PI) to produce phosphatidylinositol 3-
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phosphate (PI3P) that serves as an anchor for PI3P-binding proteins such as ATG18 to
bind to form phagophores.43 Recent studies have shown that there are two
differentPI3KC3 complexes: complex I contains PI3KC3, p150, Beclin-1 and ATG14L
whereas in complex II ATG14L is replaced by UVRAG. Complex I is involved in
Formation of phagophores while complex II contributes to autophagosome
maturation.23,43 The crescent-shaped phagophores, also known as isolation membranes,
are extended to form double-membrane autophagosomes in a process that involves two
ubiquitin-like (UBL) conjugation systems. These UBL systems function in a manner that
resembles the ubiquitylation process involved in protein degradation, which is composed
of a ubiquitin-activating enzyme (E1), a ubiquitin-conjugating enzyme (E2) and a
ubiquitin-protein ligase enzyme (E3).31,35 In the first UBL system, ATG12 is activated by
E1-like enzyme ATG7, forming an ATG12-ATG7 thioester intermediate before being
transferred to ATG10, an E2-like enzyme. In the last step ATG12 covalently binds
ATG5, and ATG12-ATG5 conjugate non-covalently interacts with ATG16L to form the
final complex. This complex dissociates from the membrane when autophagosome
formation process is complete.31,35 The second UBL system involves modification and
incorporation of microtubule-associated Protein 1 Light Chain 3 (LC3) into the
autophagosome membrane. The C-terminal region of LC3 is first cleaved by ATG4 to
form LC3-I. E1-like enzyme, ATG7, activates LC3-I, which is then transferred to ATG3,
an E2 like enzyme. In the final step, LC3-I is covalently bound to
phosphatidylethanolamine (PE) to form the lipid-protein conjugate LC3-II (Figure 7).
LC3-II is tightly associated with autophagosomes, and can be used as an autophagic
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marker in mammalian cells. Upon formation, autophagosomes are fused with lysosomes
to complete protein degradation.31,35
In addition to bulk degradation of cytoplasmic macromolecules and excessive
organelles as a result of nutrient deprivation, autophagy can also take part in degradation
of misfolded proteins. This process is mediated by the adaptor molecule p62
(sequestosome 1), which possesses specific domains to bind both the ubiquitin moiety on
the poly-ubiquitinated misfolded proteins and the LC3 on the autophagosome
membranes. Lysosomal degradation of autophagosomes results in a decrease in p62
levels, which makes p62 a suitable marker for tracking autophagy in mammalian cells.12
Autophagy can induce two opposing responses in cancer cells: protection leading
to cell survival and cytotoxicity resulting in cell death. Although toxic effects of
autophagy had been proposed to be accompanied by apoptosis, a study by Saeki et al 44
demonstrated that knock down of the anti-apoptotic protein Bcl-2 induced caspaseindependent autophagic cell death, also referred to as programmed cell death type II, by
increasing the expression of tumor suppressor Beclin-1. This study suggested that
autophagy can directly induce cell death without activating apoptotic pathways. The
important role of autophagy in tumor development is further supported by the fact that
many regulators of this process such as Beclin-1, PTEN, and PI3K/AKT/mTOR pathway
are commonly mutated or deregulated in a variety of cancers including GBM. Therefore,
the regulators of autophagy have emerged as attractive targets for development of new
cancer therapeutics.14

31

Figure 7. Autophagosome formation in mammalian cells. Inhibition of mTOR due to
amino acid starvation redepresses ULK1, which then binds ATG14L to phosphorylate
Beclin-1. Phosphorylation of Beclin 1 activates PI3KC3 in complex I leading to
production of PIP3 that in turn induces nucleation. Autophagosome formation requires
two UBL conjugation systems. UBL system 1 produces ATG5-ATG12-ATG16L1
conjugates that attach the isolation membranes and facilitate membrane nucleation. UBL
system 2 modifies LC3 and incorporates the final product, LC3-II, into the
autophagosome membrane. The final step in this process is fusion of the lysosomes with
the autophagosomes that leads to complete degradation of autophagosome contents.
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Endoplasmic Reticulum Stress
Proteins targeted for secretory pathway are folded in the lumen of endoplasmic
reticulum (ER) by chaperones before being transported to Golgi apparatus for final
modification and secretion. Interruption in this process results in accumulation of
unfolded proteins in the lumen of ER, referred to as ER stress, and induction of the
unfolded protein response (UPR). The UPR is a series of actions that collectively reduce
the rate of protein synthesis and activate transcription factors that enhance function of the
ER.49,59 There are three transmembrane proteins in the membrane of ER that sense the
accumulation of misfolded proteins and trigger the UPR: PKR-like eukaryotic initiation
factor 2α kinase (PERK), inositol requiring enzyme 1 (IRE1) and activating transcription
factor-6 (ATF6). This sensory mechanism is mediated by the chaperone protein glucoseregulated protein of 78 kDa (GRP78), also known as binding immunoglobulin protein
(BiP), present in the lumen of the ER. Under normal conditions, GRP78 is bound to the
luminal domains of PERK, IRE1 and ATF6 inhibiting their function. Upon ER stress
occurrence, GRP78 is released to bind to the unfolded protein leading to the activation of
the three stress sensors. Upon activation, ATF6 is proteolytically cleaved and directly
translocated into the nucleus to induce the expression of the genes required for the UPR.
However, activation of PERK and IRE1 is associated with dimerization and subsequent
autophosphorylation of specific residues on their cytoplasmic kinase domains.49,59
Activated IRE1, induces formation of the transcription activator spliced X-box binding
protein (XBP-1) through splicing of the XBP-1 messenger RNA whereas PERK
phosphorylates the α subunit of eukaryotic initiation factor 2 (eIF2α) (Figure 8).
Normally, GTP-bound eIF2 binds to methionyl-transfer RNA and enhances recognition
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of start codon and is released from ribosomal machinery when GTP is hydrolyzed.
Phosphorylation of the α subunit of eIF2 inhibits the exchange of GDP for GTP; thus,
reducing protein synthesis. Furthermore, activated PERK translationally controls the
expression of activating transcription factor 4 (ATF4) that induces the expression of
variable UPR-related genes involved in amino acid metabolism, regulation of oxidative
stress and apoptosis.59
To prevent aggregation of misfolded proteins in the lumen of ER during ER stress
XBP1 and ATF6 increase expression of proteins that facilitate ER-associated degradation
(ERAD). ERAD is accomplished by retrotranslocation of misfolded proteins into the
cytosol followed by ubiquitination and proteasomal degradation. ER stress can also
induce autophagy as an alternate route for protein degradation.49 As previously stated,
this process is regulated by p62, which has the proper domains to bind the ubiquitin
moiety of the misfolded proteins as well as the LC3 on the autophagosomes.12
Severe ER stress can also induce apoptosis by increasing the expression of group
III Bcl-2 family of proteins including Puma, Noxa, BIM and BID which induce the
insertion of proapoptotic proteins Bax and Bak in the mitochondrial membrane, and
consequently result in the release of cytochrome c.49 It has also been suggested that ER
stress-induced apoptosis occurs through cleavage of caspase 4, a member of caspase 1
subfamily that localizes to the ER membrane.22
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Figure 8. The mechanism of unfolded protein response.19 Upon accumulation of
unfolded proteins in the lumen of the ER, the chaperone GRP78 (BiP) is released from
the luminal domains of PERK, ATF6 and IRE1. These activated transmembrane proteins
then trigger cascades of events that collectively result in expression of UPR-related
genes. Severe ER stress can also induce apoptosis through cleavage of ER membranebound caspase 4.
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MATERIALS AND METHODS
Materials
Sorafenib Tosylate and Lapatinib Ditosylate were purchased from Selleck
Chemicals (Radnor, PA). Dr. C.D. James, (UCSF) generously provided primary human
GBM cells (GBM5, GBM6, GBM12, GBM14) and their genetic background. Dr. S.
Spiegel (VCU) kindly supplied the plasmid to express green fluorescent protein-tagged
(GFP) human LC3 for vesicle formation assay. Dulbecco’s Modified Eagle’s Medium
(DMEM), trypsin-EDTA, penicillin-streptomycin and Phosphate-buffered saline solution
(PBS) were all purchased from GIBCOBRL (Invitrogen-GIBCOBRL Life Technologies,
Grand Island, NY). Fetal bovine serum (FBS) was purchased from HyClone
Laboratories, Inc (Thermo Scientific Hyclone, South Logan, UT). Trypan blue solution,
formaldehyde, 6-Diamidino-2-Phenylidole (DAPI), and dimethyl sulfoxide (DMSO)
were all obtained from Sigma Chemical (St. Louis, MO). Recombinant adenoviruses to
express constitutively activated c-FLIP-s and Bcl-xL and dominant negative (DN)
caspase 9 were purchased from Vector Biolabs, (Philadelphia, PA). Anti-GAPDH (37
kDa, 1:1000, mouse monoclonal), anti-phospho-ERK1/2 (42, 44 kDa, 1:1000, mouse
monoclonal), anti-phospho-Akt (60 kDa, 1:1000, rabbit polyclonal), anti-phospho-eIF2α
(38 kDa, 1:1000, rabbit monoclonal), anti-puma (23 kDa, 1:1000, rabbit polyclonal), antiMcl-1 (40 kDa, 1:1000, rabbit polyclonal), anti-cleaved caspase 3 (17, 19 kDa, 1:1000,
rabbit monoclonal), anti-LC3 (14, 16 kDa, LC3II/LC3I, rabbit monoclonal), anti-P62
(SQSTM1, 65 kDa, 1:1000, mouse monoclonal), anti-GRP78 (78 kDa, 1:1000, rabbit
monoclonal), anti Beclin-1 (60 kDa, 1:1000, rabbit polyclonal) and anti-ATG5 (55 kDa,
1:1000, rabbit polyclonal) antibodies were purchased from both Cell Signaling
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Technologies (Worcester, MA), Santa Cruz Biotechnology (Santa Cruz, CA). Secondary
antibodies (IRDye 680LT Goat anti-rabbit IgG and IRDye 800CW Goat anti-mouse IgG),
and Odyssey infrared imaging system blocking buffer were obtained from LI-COR
Biosciences (Lincoln, NE). Validated siRNAs were purchased from QIAGEN (Valencia,
CA).

Methods

Cell Culture
All established glioma cell lines (GBM5, GBM6, GBM12 and GBM14),
originally derived from patients at the Mayo Clinic (Rochester, MN), were cultured in
Dulbecco’s Modified Eagle’s Medium supplemented with 5% (vol/vol) FBS and 100
µg/ml (1% vol/vol) penicillin/streptomycin. Cells were incubated in a humidified
atmosphere of 5% CO2 at 37 °C. For cell viability assays and immunoblotting, cells were
plated at a density of 2 × 104 (per well of a 12-well plate) for 24-30 hours prior to any
treatment.

Drug Treatments
Plated cells were treated with Lapatinib and Sorafenib, which were taken from a
10mM stock solution and diluted in DMSO to reach the desired concentration. The
maximal concentration of vehicle (DMSO) in media was 0.02% (v/v).
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Infection with Adenovirus:
Cells were plated in 12-well plates. 24 hours later the media was removed and
replaced by 1ml of plain DMEM (lacking FBS and penicillin-streptomycin).
Recombinant adenoviruses to express constitutively activate c-FLIP-s, Bcl-xL and
dominant negative caspase 9 or empty vector virus were added at a multiplicity of
infection (MOI) of 50. The plates were incubated for 6 hours and then the plain media
was replaced by 5% DMEM (supplemented by FBS and penicillin-steptomycin).
The cells were then treated with indicated concentration of each drug for 24/48 hours
before being subjected to trypan blue exclusion assay.

Plasmid and siRNA Transfections
For transfection, 0.5 µg of each plasmid was diluted into 50 µl of DMEM medium
with no added serum or antibiotic and was incubated in solution for 5 minutes at room
temperature. Concurrently, 1 µl of Lipofectamine 2000 reagent (Invitrogen) was diluted
into 50 µl of the same medium and was given the same incubation time. After 5 minutes,
the two solutions were mixed together and incubated at room temperature for 20 minutes.
The total mix was added to each well containing 400 µl of the same serum/antibiotic free
medium. Cells were incubated for 6 hours before equal volume (500 µl) of 10% DMEM
was added to each well. The same procedure was performed for LC3-GFP plasmid
transfection.
In order to down-regulate the expression of Beclin-1 and ATG5, a 10 nM
concentration of validated siRNA was diluted in 50 µl 0f serum-free medium. 1 µl of
Lipofectamine 2000 reagent was diluted into 50 µl of the same medium simultaneously,
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and both solutions were incubated for 5 minutes. The two solutions were then mixed and
were incubated for 20 minutes. The final solution was added to each well already
containing serum-free media. After being incubated for 6 hours, an equal volume of 10%
DMEM was added to each well.

Trypan Blue Exclusion Assay
The media from each well of the 12-well plate was transferred into a 15ml tube.
Attached cells were harvested by trypsinization with trypsin/EDTA for 5 minutes at 37°C
and then transferred into the corresponding tube. After centrifugation at 1,200 rpm for 5
minutes the supernatant was removed and the pellet was re-suspended and mixed with the
vital stain trypan blue. Insertion of trypan blue stain into the cell cytoplasm was used as
an indicator of cell death. A total of 500 cells from randomly selected fields per
experimental point were counted using a hemocytometer and a light microscope. The
percentage of dead cells was expressed as a percentage of the total number of cells
counted.

Western Blot Analysis

Cells were plated in 60 x 15mm dishes for 24 hours prior to treatment. They were
treated with the desired concentration of each drug and were incubated for 3, 6, 12 or 24
hours. After incubation, cells were lysed and scraped using whole-cell lysis buffer (0.5 M
Tris-HCl, pH 6.8, 2% (w/v) SDS, 10% (v/v) glycerol, 1% (v/v) β-mercaptoethanol,
0.02% (w/v) bromophenol blue). Collected samples were boiled for 10 minutes and then
loaded onto 8-14% sodium dodecyl sulfate–polyacrylamide gel (SDS-PAGE). Proteins
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were electrophoretically separated and transferred onto 0.45 µm PVDF membrane. The
membrane was blocked in Odyssey blocking buffer. The membrane was then exposed to
desired primary antibodies overnight. After removal of the primary antibody, the
membrane was then incubated with the corresponding goat anti-mouse or rabbit
secondary antibody for 2 hours at room temperature. After being washed three times with
TBST, the immunoblots were visualized using an Odyssey Infrared Imager (LI-COR
Biosciences, Lincoln, NE).

LC3-GFP Vesicle Formation Assay
Cells were plated in 4-well glass slide and were transfected with the LC3-GFP
plasmid. 24 hours after transfection, cells were treated with the indicated drugs and were
visualized on a ZeissAxiovert 200 micoscope (Carl Zeiss, Wake Forest, NC) 6, 12 and 24
hours after the treatment. The number of vesicles in 40 cells representing each group was
counted, and the average vesicles formed in each group was calculated.

Data Analysis
The effects of various treatments were analyzed using one-way analysis of
variance and a two-tailed Student’s t-test. Results with a P value of <0.05 were
considered statistically significant.
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Results
Sorafenib (also referred to as Sor) and lapatinib (also referred to as Lap) have
recently been subjected to numerous clinical trials either individually or in combination
with other anticancer agents. First, a dose response test was performed for both drugs
within the clinically relevant range (Figure 9). Afterwards, both GBM5 and GBM12 cells
were treated with DMSO, serving as the vehicle group (also referred to as Veh), and a
combination of either, 1 µM lapatinib and 3 µM sorafenib (not shown) or 2 µM lapatinib
and 3 µM or 6 µM sorafenib (Figure 10 and 11). Viability was determined by trypan blue
exclusion assay after 48 hours of drug exposure. The combination of 2 µM lapatinib and
6 µM sorafenib in both GBM5 and GBM12 led to cell death in a greater than additive
manner (Figure 10B and 11B). Conversely, lapatinib (2 µM) in combination with a lower
concentration of sorafenib (3 µM) failed to produce a similar effect (Figure 10A and
11A). Therefore, the combination of 2 µM lapatinib and 6 µM sorafenib was selected for
all other experiments performed in this manuscript.
This selected therapeutic combination effectively induced cell death in a greater
than additive manner regardless of differing cell type dependent mutations. This was
made evident after treatment of GBM6 cells, which express EGFRvIII and GBM14 cells,
which express mutant PTEN, yielded in similar results (Figure 12).
Considering that all GBM cell lines responded similarly to combinational
treatment with sorafenib and lapatinib, GBM5 and GBM12 cells were utilized for further
experimentation.
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Figure 9. Lapatinib and sorafenib dose response in GBM12 cells.
GBM12 cells were treated with varying concentrations of lapatinib (A) and sorafenib (B)
within the clinically relevant range, and cell viability was determined by trypan blue
exclusion assay 48 hours after drug exposure.
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Figure 10. Assessment of cell viability in GBM5 cells treated with lapatinib and
sorafenib. GBM5 cells were treated with 2 µM lapatinib combined with two different
concentrations of 3 µM (A) or 6 µM (B) sorafenib, and cell viability was determined by
trypan blue exclusion assay 48 hours after drug exposure.
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Figure 11. Assessment of cell viability in GBM12 cells treated with lapatinib and
sorafenib. GBM12 cells were treated with 2 µM lapatinib combined with two different
concentrations of 3 µM (A) or 6 µM (B) sorafenib and cell viability was determined by
trypan blue exclusion assay 48 hours after drug exposure.
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Figure 12. Assessment of cell viability in GBM6 and GBM14 cells treated with
lapatinib and sorafenib. GBM6 (A) and GBM14 (B) cells were treated with either
lapatinib (2 µM) or sorafenib (6 µM) alone or the combination and cell viability was
determined by trypan blue exclusion assay 48 hours after drug exposure.
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Western blot analysis
To investigate the mechanisms involved in the activation of apoptosis and
autophagy and to pinpoint the major growth signaling pathways that are affected by the
combinatorial effect of sorafenib and lapatinib, GBM12 cell lysates were collected 3, 6,
12 and 24 hours after treatment. The samples were then probed for the proteins involved
in endoplasmic reticulum stress, autophagy and apoptosis via western blot analysis. The
data indicated that combinational treatment with lapatinib and sorafenib led to the
activation of ER stress, as well as the autophagic and apopototic pathways alongside
inhibition of MAP kinase and PI3K/AKT pathways.
As stated previously, both sorafenib and lapatinib inhibit MAP kinase pathway
through inhibition of Raf kinase and EGFR tyrosine kinases respectively. This effect was
made evident by the decreasing level of phospho-ERK1/2 observed in response to this
therapeutic treatment. Phosphorylation of ERK1/2 was modestly inhibited by lapatinib,
whereas sorafenib demonstrated a greater inhibitory effect. Conversely, the combination
of sorafenib and lapatinib dramatically reduced the phosphorylation of ERK1/2,
emphasizing the therapeutic benefit of using these drugs simultaneously.
In addition, an increase in phosphorylation of eIF2α in response to sorafenib as
well as the combination of both drugs is a solid indicator of the induction of the unfolded
protein response. Accordingly, the expression of Mcl-1 was down-regulated in the same
groups that demonstrated an increase in phosphorylation of eIF2α. Furthermore, a rapid
decrease in GRP78 level in response to sorafenib and the combination of sorafenib and
lapatinib was observed 12 hours after treatment.
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It was also noted that treatment with lapatinib or sorafenib led to inhibition of the
PI3K/AKT pathway. Sorafenib individually, and in combination with lapatinib, resulted
in more potent inhibition in phosphorylation of AKT compared to lapatinib alone.
The induction of autophagy was also investigated by examining the expression of
LC3 isoforms (LC3A and LC3B), Beclin-1 and p62 (sequestosome 1). Increasing levels
of total LC3A/B and Beclin-1, predominantly due to exposure of cells to sorafenib or the
combination of sorafenib and lapatinib, suggested activation of autophagy indicated by
the presence of autophagosomes. A decrease in p62 level in cells treated with sorafenib
or the combination is an indicator of lysosomal degradation. Interestingly, in lapatinibtreated cells, accumulation of p62 revealed a surprising stall in protein degradation.
Finally, an increase in the level of Puma, primarily caused by lapatinib could be
assumed as an indicator of apoptosis.
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Figure 13. Western blot analysis of GBM12 cells at 3, 6, 12 and 24 hours after
exposure to sorafenib and lapatinib. GBM12 cells were treated with lapatinib (2 µM),
sorafenib (6 µM) or the combination. Cell lysates were collected at 3, 6, 12 and 24 hours
after the treatment. The samples were then probed for target proteins.
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The role of autophagy and formation of LC3-GFP vesicle formation in GBM12 cells
GBM12 cells plated in four-well chamber slides were transfected with a plasmid
containing LC3-GFP construct, and the formation of the autophagic vesicles was assessed
by fluorescent microscopy at 6, 12 and 24 hours after the treatment, respectively (Figure
14A). The number of vesicles in 40 cells representing each group was counted, and the
average vesicles formed in each group was calculated (Figure 14B). The data showed a
significant increase in the formation of autophagic vesicles in GBM12 cells as early as 6
hours after treatment with sorafenib and the combination. This trend stabilized after 12
hours, with vesicle formation remaining higher after combinational treatment. The extent
of autophagy in the lapatinib-treated groups was not significant.
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Figure 14. LC3-GFP vesicle formation assay in GBM12 cells treated with sorafenib
and lapatinib. GBM12 cells were transfected with LC3-GFP plasmid and treated with
lapatinib (2 µM), sorafenib (6 µM) and the combination. Cells were then visualized by
fluorescent microscopy at 6, 12 and 24 hours after exposure (A). The number of vesicles
in 40 cells representing each group was counted, and the average vesicles formed in each
group was calculated and plotted (B).
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Knockdown of ATG5 and Beclin 1 reduces the drug combination-mediated toxicity
in GBM12 and GBM5 cells
In order to investigate the role of autophagy in lapatinib and sorafenib-mediated
cell death, Beclin1 and ATG5 were down-regulated. GBM12 and GBM5 cells were
transfected with control siRNA (SCR), siBeclin1 or siATG5 then subjected to lapatinib,
sorafenib and the combination of both agents for 24 hours after which cell viability was
assessed by trypan blue exclusion assay. The results revealed a reduction in cellular
toxicity in response to sorafenib and sorafenib with lapatinib. Toxicity of lapatinib was
not affected by inhibition of autophagy (Figure 15 and 16). These findings agreed with
the data gained from the LC3-GFP vesicle formation assay, emphasizing the significance
of autophagy in lapatinib and sorafenib combination-mediated toxicity.
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Figure 15. Knockdown of ATG5 and Beclin-1 reduces drug combination-mediated
toxicity in GBM12 cells. GBM12 cells were first transfected with either siATG5 or
siBeclin-1 and then treated with lapatinib (2 µM) and sorafenib (6 µM) or the
combination. Cell viability was determined by trypan blue exclusion assay 24 hours after
exposure. *P<0.05 less than corresponding value in siSCR cells.
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Figure 16. Knockdown of ATG5 and Beclin-1 reduces drug combination-mediated
toxicity in GBM5 cells. GBM5 cells were first transfected with either siATG5 or
siBeclin-1 and then treated with lapatinib (2 µM) and sorafenib (6 µM) or the
combination. Cell viability was determined by trypan blue exclusion assay 24 hours after
exposure. *P<0.05 less than corresponding value in siSCR cells.
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Up-regulation of FLIP and Bcl-xL and down-regulation of caspase 9 reduce the
drug combination-mediated toxicity in GBM12 and GBM5 cells
To elucidate the involvement of apoptosis in drug-mediated cell death, GBM12
and GBM 5 cells were infected with adenoviruses carrying an empty vector (CMV) or the
constructs designed to either down-regulate caspase 9 via dominant negative mutation
(DN9) or up-regulate the expression of FLIP or Bcl-xL. Transfected cells were treated
with sorafenib and lapatinib or the combination for 24 hours and cell viability was
determined by trypan blue exclusion assay. In GBM12 cells, knockdown of caspase-9, a
key component of the intrinsic apoptotic pathway, and overexpression of Bcl-xL, an
antiapoptotic protein, reduced the toxicity of lapatinib and the combination whereas the
toxicity of sorafenib remained intact. On the other hand, overexpression of FLIP, an
inhibitor of caspase 8, decreased cell death caused by both sorafenib and the drug
combination, whereas the toxicity of lapatinib was not affected (Figure 17 and 18). In
GBM5 cells down-regulation of caspase 9 and up-regulation of Bcl-xL produced similar
results. However, overexpression of FLIP reduced the toxicity of sorafenib and lapatinib
individually and in combination (Figure 19). The role of the intrinsic and extrinsic
apoptotic pathways in drug-mediated cell death was more clearly observed in GBM12
cells after 48 hour exposure (Figure 20).
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Figure 17. Overexpression of FLIP and Bcl-xL reduces the toxicity of the drug
combination in GBM12 cells. GBM12 cells were first infected with recombinant
adenoviruses to express constitutively activate FLIP and Bcl-xL and then were treated
with lapatinib (2 µM), sorafenib (6 µM) and the combination. Cell viability was assessed
by trypan blue exclusion assay 24 hours after exposure. *P<0.05 less than corresponding
value in CMV cells.
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Figure 18. Down-regulation of caspase 9 reduces the toxicity of the drug
combination in GBM12 cells. GBM12 cells were infected with the recombinant
adenovirus expressing mutant dominant negative caspase 9. Cells were then treated with
lapatinib (2 µM), sorafenib (6 µM) and the combination. Cell viability was assessed by
trypan blue exclusion assay 24 hours after exposure. *P<0.05 less than corresponding
value in CMV cells.
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Figure 19. Up-regulation of FLIP and Bcl-xL and down-regulation of caspase 9
reduce the toxicity of the drug combination in GBM5 cells. GBM5 cells were infected
with recombinant adenoviruses to express constitutively activate FLIP, Bcl-xL and
dominant negative caspase 9. Cells were then treated with lapatinib (2 µM), sorafenib (6
µM) and the combination. Cell viability was assessed by trypan blue exclusion assay 24
hours after exposure. *P<0.05 less than corresponding value in CMV cells.
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Figure 20. Up-regulation of FLIP and down-regulation of caspase 9 dramatically
reduce the toxicity of the drug combination in GBM12 cells during 48 hour-drug
exposure. GBM12 cells were infected with the recombinant adenoviruses expressing
mutant dominant negative caspase 9 and constitutively active FLIP. Cells were then
treated with lapatinib (2 µM) and sorafenib (6 µM) simultaneously. Cell viability was
assessed by trypan blue exclusion assay 48 hours after exposure. *P<0.05 less than
corresponding value in CMV cells.
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Knockdown of Fas and FADD reduces the drug combination-mediated toxicity in
GBM12 cells
Previous data suggested the involvement of receptor-mediated apoptosis in cells
treated with sorafenib and the combination of sorafenib and lapatinib. In order to
elucidate which members of TNF receptor family are involved in this process, Fas and
Fas-associated death domain (FADD) were knocked down by corresponding siRNAs and
cell viability was assessed by trypan blue exclusion assay 24 hours after the treatment.
The results indicated a reduction in toxicity of the drug combination; further confirming
activation of extrinsic apoptotic pathways (Figure 21).
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Figure 21. Knockdown of CD95 (Fas) and FADD reduce the toxicity of the drug
combination in GBM12 cells. GBM12 cells were first transfected with either siCD95 or
siFADD and then treated with the combination of lapatinib (2 µM) and sorafenib (6 µM).
Cell viability was determined by trypan blue exclusion assay 24 hours after exposure.
*P<0.05 less than corresponding value in siSCR cells.
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Discussion
Although the EGFR signaling pathway is commonly deregulated in GBMs, most
clinical trials utilizing EGFR inhibitors have not yielded any beneficial outcome. This, in
part, is due to acquired resistance by which GBM cells bypass the dreadful effects of the
targeted therapeutics such as lapatinib.7 As previously stated, acquiring resistance may be
through secondary mutations in ErbB receptors, or through crosstalk and activation of
parallel signaling pathways, or by up-regulation of prosurvival proteins such as Mcl-1.8
In addition, Akhavan et al 1 recently showed that de-repression of PDGFRβ,
predominantly due to ERK activity, promotes resistance to EGFR inhibitors in
glioblastoma. Moreover, Fenton et al 15 suggested that acquired resistance to EGFR
inhibitors in glioblastoma is mediated by phosphorylation of PTEN at tyrosine 240 which
leads to loss of PTEN function, through loss of membrane interaction, and consequent
activation of PI3K/AKT pathway. Since sorafenib is a potent PDGFRβ inhibitor 30,53, and
has the ability to down-regulate Mcl-140,41 and phospho-AKT 64, we hypothesized that
sorafenib can enhance lapatinib toxicity and improve the treatment efficacy.
Sorafenib and lapatinib are FDA- approved targeted therapeutics, and their toxic
effects have been well tolerated by adult patients who received up to 800 mg/day of
sorafenib or 1500 mg/day of lapatinib.6,52 Assessing the cell viability in GBM5, GBM6,
GBM12 and GBM14 cells treated with the combination of these agents within the
clinically relevant dose range, we demonstrated that 2 µM lapatinib in combination with
6 µM sorafenib kill GBM tumor cells in a greater than additive manner (Figure 10B, 11B
and 12). We also elucidated the mechanisms involved in this drug-mediated cell death.
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Rahmani et al 40,41 formerly demonstrated that down-regulation of Mcl-1 by
sorafenib is independent of caspase activation and MEK1/2/ERK1/2 pathway, and
suggested that sorafenib exerts this effect in a PERK dependent manner. They proposed
activation of PERK followed by subsequent phosphorylation of eIF2α inhibited protein
translation leading to a rapid decline of Mcl-1 due to its short half-life.40,41 As
demonstrated in figure 13, an increase in phosphorylation of eIF2α accompanied by a
rapid decrease in Mcl-1 level in GBM12 cells starting 6 hours after the treatment with
sorafenib and the combination of sorafenib and lapatinib further approves inhibition of
translation of Mcl-1 through activation of PERK. Even though activation of PERK is a
solid indicator of ER stress, interestingly, the level of GRP78, a chaperone with
cytoprotective function, declined rapidly in response to sorafenib 12 hours after the
treatment (Figure 13). According to Rahmani et al 41, a reduction in GRP78 production,
predominantly due to inhibition of Raf/MEK1/2/ERK1/2 pathway (decrease in phosphoERK1/2 shown in figure 13), contributes to sorafenib-mediated lethality but it is not
critical since activation of MEK1 did not disrupt sorafenib-mediated cell death.
Therefore, in this study we further investigated plausible apoptotic pathways that are
activated in response to sorafenib and lapatinib through overexpressing FLIP or Bcl-xL
or down-regulating caspase 9. Knockdown of caspase 9 or overexpression of Bcl-xL in
GBM12 and GBM 5 cells reduced the toxicity of lapatinib (Figure 18 and 19) suggesting
that lapatinib induces cell death through activation of intrinsic apoptotic pathway, which
leads to permeabilization of mitochondrial membrane and consequently the release of
cytochrome c and other apoptotic factors. Elevated level of Puma, a Bcl-2 family member
that promotes insertion of Bax and Bak in the mitochondrial membrane, observed as early
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as 3 hours after exposure to lapatinib confirms activation of porapoptotic proteins.
Conversely, toxicity of sorafenib was not affected by down-regulation of caspase 9. On
the other hand, overexpression of FLIP in the same cells suppressed toxicity of sorafenib
indicating that sorafenib exerts its toxic effect mainly through activation of
transmembrane death receptors (Figure 17 and 19). Among the members of TNFR
family, Fas (CD95) and its associated death domain, FADD, were shown to be involved
in this process since the knockdown of both Fas and FADD reduced combinationmediated cell death in GBM12 cells (Figure 21). Overexpression of FLIP did not affect
lapatinib-mediated cell death in GBM12 cells whereas in GBM5 cells a reduction in
lapatinib toxicity was observed indicating that lapatinib-mediated cell death in GBM5
cells might involve activation of both intrinsic and extrinsic pathways through crosstalk
between these two cascades. Overall, our data suggested the combination of sorafenib
and lapatinib induced cell death in GBM12 and GBM5 cells through activation of both
intrinsic and extrinsic apoptotic pathways, and inhibition of each pathway individually
resulted in a dramatic reduction in combination-mediated cell death 48 hours after drug
exposure (Figure 20).
In addition to apoptosis, induction of autophagy was also investigated through
LC3-GFP vesicle formation assay, western blot analysis and knock down of ATG5 and
Beclin 1. LC3-GFP vesicle formation assay in GBM12 cells demonstrated a significant
increase in the formation of autophagic vesicles as early as 6 hours after treatment with
sorafenib and the combination of sorafenib and lapatinib (figure 14). Western blot
analysis also showed an increase in total LC3 (isoforms A and B) and Beclin 1 in
response to the drugs, both individually and in combination (Figure 13). However,
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evidently sorafenib and the combination of both drugs applied a much stronger effect in
overexpression of Beclin 1 and formation of autophagosomes. In order to determine the
role of autophagy in drug-mediated cell death, ATG5 and Beclin 1 were knocked down
individually in both GBM12 and GBM5 cells. The data showed that inhibition of
autophagy reduced cell death in cells treated with sorafenib and the combination whereas
lapatinib-mediated toxicity remained intact. Whether this effect is due to induction of
cytotoxic autophagy or it occurs in a caspase-dependent manner requires more
investigation. Surprisingly, accumulation of p62 was observed within the first 6 hours of
lapatinib exposure in GBM12 cells (Figure 13) showing a stall in lysosomal degradation
of ubiquitin-tagged proteins. This phenomenon was not observed in cells exposed to
sorafenib and the combination of both agents, and autophagosome formation was
followed by lysosomal degradation.

Conclusion
In conclusion, in this study we demonstrated that sorafenib in combination with
lapatinib kill GBM tumor cells in a greater than additive manner in a process that
involves induction of ER stress, autophagy, intrinsic and extrinsic apoptotic pathways.
Sorafenib induces cell death mainly through activation of Fas and recruitment of FADD
whereas lapatinib triggers mitochondria-mediated cell death. We also showed that
inhibition of autophagy reduced combination-mediated cell death suggesting either the
occurrence of cytotoxic autophagy or activation of caspase-dependent pathways.

65

Bibliography

1. Akhavan, D., Pourzia, A. L., Nourian, A. A., Williams, K. J., Nathanson, D.,
Babic, I., et al. (2013). De-repression of PDGFRbeta transcription promotes
acquired resistance to EGFR tyrosine kinase inhibitors in glioblastoma patients.
Cancer Discovery, 3(5), 534-547. doi:10.1158/2159-8290.CD-12-0502;
10.1158/2159-8290.CD-12-0502
2. Amaravadi, R. K., & Thompson, C. B. (2007). The roles of therapy-induced
autophagy and necrosis in cancer treatment. Clinical Cancer Research : An
Official Journal of the American Association for Cancer Research, 13(24), 72717279. doi:10.1158/1078-0432.CCR-07-1595
3. Arora, A., & Scholar, E. M. (2005). Role of tyrosine kinase inhibitors in cancer
therapy. The Journal of Pharmacology and Experimental Therapeutics, 315(3),
971-979. doi:10.1124/jpet.105.084145
4. Carico, C., Nuno, M., Mukherjee, D., Elramsisy, A., Dantis, J., Hu, J., et al.
(2012). Loss of PTEN is not associated with poor survival in newly diagnosed
glioblastoma patients of the temozolomide era. PloS One, 7(3), e33684.
doi:10.1371/journal.pone.0033684; 10.1371/journal.pone.0033684
5. Carmo, A., Carvalheiro, H., Crespo, I., Nunes, I., & Lopes, M. C. (2011). Effect
of temozolomide on the U-118 glioma cell line. Oncology Letters, 2(6), 11651170. doi:10.3892/ol.2011.406
6. Chu, Q. S., Cianfrocca, M. E., Goldstein, L. J., Gale, M., Murray, N., Loftiss, J.,
et al. (2008). A phase I and pharmacokinetic study of lapatinib in combination
with letrozole in patients with advanced cancer. Clinical Cancer Research : An
66

Official Journal of the American Association for Cancer Research, 14(14), 44844490. doi:10.1158/1078-0432.CCR-07-4417; 10.1158/1078-0432.CCR-07-4417
7. Clark, P. A., Iida, M., Treisman, D. M., Kalluri, H., Ezhilan, S., Zorniak, M., et al.
(2012). Activation of multiple ERBB family receptors mediates glioblastoma
cancer stem-like cell resistance to EGFR-targeted inhibition. Neoplasia (New
York, N.Y.), 14(5), 420-428.
8. Cruickshanks, N., Hamed, H. A., Bareford, M. D., Poklepovic, A., Fisher, P. B.,
Grant, S., et al. (2012). Lapatinib and obatoclax kill tumor cells through blockade
of ERBB1/3/4 and through inhibition of BCL-XL and MCL-1. Molecular
Pharmacology, 81(5), 748-758. doi:10.1124/mol.112.077586;
10.1124/mol.112.077586
9. Cully, M., You, H., Levine, A. J., & Mak, T. W. (2006). Beyond PTEN
mutations: The PI3K pathway as an integrator of multiple inputs during
tumorigenesis. Nature Reviews.Cancer, 6(3), 184-192. doi:10.1038/nrc1819
10. Dasgupta, T., & Haas-Kogan, D. A. (2013). The combination of novel targeted
molecular agents and radiation in the treatment of pediatric gliomas. Frontiers in
Oncology, 3, 110. doi:10.3389/fonc.2013.00110; 10.3389/fonc.2013.00110
11. Dhillon, A. S., Hagan, S., Rath, O., & Kolch, W. (2007). MAP kinase signalling
pathways in cancer. Oncogene, 26(22), 3279-3290. doi:10.1038/sj.onc.1210421
12. Ding, W. X., & Yin, X. M. (2008). Sorting, recognition and activation of the
misfolded protein degradation pathways through macroautophagy and the
proteasome. Autophagy, 4(2), 141-150.

67

13. Elmore, S. (2007). Apoptosis: A review of programmed cell death. Toxicologic
Pathology, 35(4), 495-516. doi:10.1080/01926230701320337
14. Fan, Q. W., & Weiss, W. A. (2011). Autophagy and akt promote survival in
glioma. Autophagy, 7(5), 536-538.
15. Fenton, T. R., Nathanson, D., Ponte de Albuquerque, C., Kuga, D., Iwanami, A.,
Dang, J., et al. (2012). Resistance to EGF receptor inhibitors in glioblastoma
mediated by phosphorylation of the PTEN tumor suppressor at tyrosine 240.
Proceedings of the National Academy of Sciences of the United States of America,
109(35), 14164-14169. doi:10.1073/pnas.1211962109; 10.1073/pnas.1211962109
16. Gan, H. K., Cvrljevic, A. N., & Johns, T. G. (2013). The epidermal growth factor
receptor variant III (EGFRvIII): Where wild things are altered. The FEBS
Journal, 280(21), 5350-5370. doi:10.1111/febs.12393; 10.1111/febs.12393
17. Gao, Q., Lei, T., & Ye, F. (2013). Therapeutic targeting of EGFR-activated
metabolic pathways in glioblastoma. Expert Opinion on Investigational Drugs,
22(8), 1023-1040. doi:10.1517/13543784.2013.806484;
10.1517/13543784.2013.806484
18. Hainsworth, J. D., Ervin, T., Friedman, E., Priego, V., Murphy, P. B., Clark, B.
L., et al. (2010). Concurrent radiotherapy and temozolomide followed by
temozolomide and sorafenib in the first-line treatment of patients with
glioblastoma multiforme. Cancer, 116(15), 3663-3669. doi:10.1002/cncr.25275;
10.1002/cncr.25275
19. Hamed, H. (2012). MDA-7/IL-24; a promising cancer therapeutic agent.

68

20. Hegi, M. E., Diserens, A. C., Gorlia, T., Hamou, M. F., de Tribolet, N., Weller,
M., et al. (2005). MGMT gene silencing and benefit from temozolomide in
glioblastoma. The New England Journal of Medicine, 352(10), 997-1003.
doi:10.1056/NEJMoa043331
21. Hirose, Y., Katayama, M., Mirzoeva, O. K., Berger, M. S., & Pieper, R. O.
(2005). Akt activation suppresses Chk2-mediated, methylating agent-induced G2
arrest and protects from temozolomide-induced mitotic catastrophe and cellular
senescence. Cancer Research, 65(11), 4861-4869. doi:10.1158/0008-5472.CAN04-2633
22. Hitomi, J., Katayama, T., Eguchi, Y., Kudo, T., Taniguchi, M., Koyama, Y., et al.
(2004). Involvement of caspase-4 in endoplasmic reticulum stress-induced
apoptosis and abeta-induced cell death. The Journal of Cell Biology, 165(3), 347356. doi:10.1083/jcb.200310015
23. Itakura, E., & Mizushima, N. (2009). Atg14 and UVRAG: Mutually exclusive
subunits of mammalian beclin 1-PI3K complexes. Autophagy, 5(4), 534-536.
24. Kane, R. C., Farrell, A. T., Saber, H., Tang, S., Williams, G., Jee, J. M., et al.
(2006). Sorafenib for the treatment of advanced renal cell carcinoma. Clinical
Cancer Research : An Official Journal of the American Association for Cancer
Research, 12(24), 7271-7278. doi:10.1158/1078-0432.CCR-06-1249
25. Kolch, W., Kotwaliwale, A., Vass, K., & Janosch, P. (2002). The role of raf
kinases in malignant transformation. Expert Reviews in Molecular Medicine, 4(8),
1-18. doi:doi:10.1017/S1462399402004386

69

26. Kumar, K. K., Nagoji, K. E., & Nadh, R. V. (2012). A validated RP-HPLC
method for the estimation of lapatinib in tablet dosage form using gemcitabine
hydrochloride as an internal standard. Indian Journal of Pharmaceutical Sciences,
74(6), 580-583. doi:10.4103/0250-474X.110621; 10.4103/0250-474X.110621
27. Lantz, E., Cunningham, I., & Higa, G. M. (2010). Targeting HER2 in breast
cancer: Overview of long-term experience. International Journal of Women's
Health, 1, 155-171.
28. Li, H., Zhu, H., Xu, C. J., & Yuan, J. (1998). Cleavage of BID by caspase 8
mediates the mitochondrial damage in the fas pathway of apoptosis. Cell, 94(4),
491-501.
29. Lino, M. M., & Merlo, A. (2011). PI3Kinase signaling in glioblastoma. Journal of
Neuro-Oncology, 103(3), 417-427. doi:10.1007/s11060-010-0442-z;
10.1007/s11060-010-0442-z
30. Liu, L., Cao, Y., Chen, C., Zhang, X., McNabola, A., Wilkie, D., et al. (2006).
Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and
induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.
Cancer Research, 66(24), 11851-11858. doi:10.1158/0008-5472.CAN-06-1377
31. Marino, G., & Lopez-Otin, C. (2004). Autophagy: Molecular mechanisms,
physiological functions and relevance in human pathology. Cellular and
Molecular Life Sciences : CMLS, 61(12), 1439-1454. doi:10.1007/s00018-0044012-4
32. Martin, A. P., Miller, A., Emad, L., Rahmani, M., Walker, T., Mitchell, C., et al.
(2008). Lapatinib resistance in HCT116 cells is mediated by elevated MCL-1

70

expression and decreased BAK activation and not by ERBB receptor kinase
mutation. Molecular Pharmacology, 74(3), 807-822.
doi:10.1124/mol.108.047365; 10.1124/mol.108.047365
33. Martin, A. P., Mitchell, C., Rahmani, M., Nephew, K. P., Grant, S., & Dent, P.
(2009). Inhibition of MCL-1 enhances lapatinib toxicity and overcomes lapatinib
resistance via BAK-dependent autophagy. Cancer Biology & Therapy, 8(21),
2084-2096.
34. Mitchell, C., Yacoub, A., Hossein, H., Martin, A. P., Bareford, M. D., Eulitt, P., et
al. (2010). Inhibition of MCL-1 in breast cancer cells promotes cell death in vitro
and in vivo. Cancer Biology & Therapy, 10(9), 903-917.
doi:10.4161/cbt.10.9.13273; 10.4161/cbt.10.9.13273
35. Mizushima, N., Ohsumi, Y., & Yoshimori, T. (2002). Autophagosome formation
in mammalian cells. Cell Structure and Function, 27(6), 421-429.
36. Mrugala, M. M., & Chamberlain, M. C. (2008). Mechanisms of disease:
Temozolomide and glioblastoma--look to the future. Nature Clinical
Practice.Oncology, 5(8), 476-486. doi:10.1038/ncponc1155; 10.1038/ncponc1155
37. Oda, E., Ohki, R., Murasawa, H., Nemoto, J., Shibue, T., Yamashita, T., et al.
(2000). Noxa, a BH3-only member of the bcl-2 family and candidate mediator of
p53-induced apoptosis. Science (New York, N.Y.), 288(5468), 1053-1058.
38. Patel, M., Vogelbaum, M. A., Barnett, G. H., Jalali, R., & Ahluwalia, M. S.
(2012). Molecular targeted therapy in recurrent glioblastoma: Current challenges
and future directions. Expert Opinion on Investigational Drugs, 21(9), 1247-1266.
doi:10.1517/13543784.2012.703177; 10.1517/13543784.2012.703177

71

39. Patil, C. G., Nuno, M., Elramsisy, A., Mukherjee, D., Carico, C., Dantis, J., et al.
(2013). High levels of phosphorylated MAP kinase are associated with poor
survival among patients with glioblastoma during the temozolomide era. NeuroOncology, 15(1), 104-111. doi:10.1093/neuonc/nos272; 10.1093/neuonc/nos272
40. Rahmani, M., Davis, E. M., Bauer, C., Dent, P., & Grant, S. (2005). Apoptosis
induced by the kinase inhibitor BAY 43-9006 in human leukemia cells involves
down-regulation of mcl-1 through inhibition of translation. The Journal of
Biological Chemistry, 280(42), 35217-35227. doi:10.1074/jbc.M506551200
41. Rahmani, M., Davis, E. M., Crabtree, T. R., Habibi, J. R., Nguyen, T. K., Dent,
P., et al. (2007). The kinase inhibitor sorafenib induces cell death through a
process involving induction of endoplasmic reticulum stress. Molecular and
Cellular Biology, 27(15), 5499-5513. doi:10.1128/MCB.01080-06
42. Roberts, P. J., & Der, C. J. (2007). Targeting the raf-MEK-ERK mitogenactivated protein kinase cascade for the treatment of cancer. Oncogene, 26(22),
3291-3310. doi:10.1038/sj.onc.1210422
43. Russell, R. C., Tian, Y., Yuan, H., Park, H. W., Chang, Y. Y., Kim, J., et al.
(2013). ULK1 induces autophagy by phosphorylating beclin-1 and activating
VPS34 lipid kinase. Nature Cell Biology, 15(7), 741-750. doi:10.1038/ncb2757;
10.1038/ncb2757
44. Saeki, K., Yuo, A., Okuma, E., Yazaki, Y., Susin, S. A., Kroemer, G., et al.
(2000). Bcl-2 down-regulation causes autophagy in a caspase-independent
manner in human leukemic HL60 cells. Cell Death and Differentiation, 7(12),
1263-1269. doi:10.1038/sj.cdd.4400759

72

45. Sami, A., & Karsy, M. (2013). Targeting the PI3K/AKT/mTOR signaling
pathway in glioblastoma: Novel therapeutic agents and advances in
understanding. Tumour Biology : The Journal of the International Society for
Oncodevelopmental Biology and Medicine, 34(4), 1991-2002.
doi:10.1007/s13277-013-0800-5; 10.1007/s13277-013-0800-5
46. Scaltriti, M., Verma, C., Guzman, M., Jimenez, J., Parra, J. L., Pedersen, K., et al.
(2009). Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and
accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity.
Oncogene, 28(6), 803-814. doi:10.1038/onc.2008.432; 10.1038/onc.2008.432
47. Schmidt-Ullrich, R. K., Contessa, J. N., Lammering, G., Amorino, G., & Lin, P.
S. (2003). ERBB receptor tyrosine kinases and cellular radiation responses.
Oncogene, 22(37), 5855-5865. doi:10.1038/sj.onc.1206698
48. Schmitz, I., Kirchhoff, S., & Krammer, P. H. (2000). Regulation of death
receptor-mediated apoptosis pathways. The International Journal of Biochemistry
& Cell Biology, 32(11-12), 1123-1136.
49. Schroder, M. (2008). Endoplasmic reticulum stress responses. Cellular and
Molecular Life Sciences : CMLS, 65(6), 862-894. doi:10.1007/s00018-007-73835
50. Shacham-Shmueli, E., Geva, R., Figer, A., Bulocinic, S., Nalbandyan, K.,
Shpigel, S., et al. (2012). Phase I trial of sorafenib in combination with 5fluorouracil/leucovorin in advanced solid tumors. Journal of Clinical
Pharmacology, 52(5), 656-669. doi:10.1177/0091270011404027;
10.1177/0091270011404027

73

51. Sharma, K., Wang, R. X., Zhang, L. Y., Yin, D. L., Luo, X. Y., Solomon, J. C., et
al. (2000). Death the fas way: Regulation and pathophysiology of CD95 and its
ligand. Pharmacology & Therapeutics, 88(3), 333-347.
52. Shinsako, K., Mizuno, T., Terada, T., Watanabe, J., Kamba, T., Nakamura, E., et
al. (2010). Tolerable sorafenib therapy for a renal cell carcinoma patient with
hemodialysis: A case study. International Journal of Clinical Oncology, 15(5),
512-514. doi:10.1007/s10147-010-0070-9; 10.1007/s10147-010-0070-9
53. Siegelin, M. D., Raskett, C. M., Gilbert, C. A., Ross, A. H., & Altieri, D. C.
(2010). Sorafenib exerts anti-glioma activity in vitro and in vivo. Neuroscience
Letters, 478(3), 165-170. doi:10.1016/j.neulet.2010.05.009;
10.1016/j.neulet.2010.05.009
54. Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn,
M. J., et al. (2005). Radiotherapy plus concomitant and adjuvant temozolomide
for glioblastoma. The New England Journal of Medicine, 352(10), 987-996.
doi:10.1056/NEJMoa043330
55. Takahashi, Y., Meyerkord, C. L., Hori, T., Runkle, K., Fox, T. E., Kester, M., et
al. (2011). Bif-1 regulates Atg9 trafficking by mediating the fission of golgi
membranes during autophagy. Autophagy, 7(1), 61-73.
56. Tang, Y., Hamed, H. A., Cruickshanks, N., Fisher, P. B., Grant, S., & Dent, P.
(2012). Obatoclax and lapatinib interact to induce toxic autophagy through
NOXA. Molecular Pharmacology, 81(4), 527-540. doi:10.1124/mol.111.076851;
10.1124/mol.111.076851

74

57. Tang, Y., Yacoub, A., Hamed, H. A., Poklepovic, A., Tye, G., Grant, S., et al.
(2012). Sorafenib and HDAC inhibitors synergize to kill CNS tumor cells. Cancer
Biology & Therapy, 13(7), 567-574. doi:10.4161/cbt.19771; 10.4161/cbt.19771
58. Thiessen, B., Stewart, C., Tsao, M., Kamel-Reid, S., Schaiquevich, P., Mason,
W., et al. (2010). A phase I/II trial of GW572016 (lapatinib) in recurrent
glioblastoma multiforme: Clinical outcomes, pharmacokinetics and molecular
correlation. Cancer Chemotherapy and Pharmacology, 65(2), 353-361.
doi:10.1007/s00280-009-1041-6; 10.1007/s00280-009-1041-6
59. Wek, R. C., & Cavener, D. R. (2007). Translational control and the unfolded
protein response. Antioxidants & Redox Signaling, 9(12), 2357-2371.
doi:10.1089/ars.2007.1764
60. Wilhelm, S., Carter, C., Lynch, M., Lowinger, T., Dumas, J., Smith, R. A., et al.
(2006). Discovery and development of sorafenib: A multikinase inhibitor for
treating cancer. Nature Reviews.Drug Discovery, 5(10), 835-844.
doi:10.1038/nrd2130
61. Wilhelm, S. M., Adnane, L., Newell, P., Villanueva, A., Llovet, J. M., & Lynch,
M. (2008). Preclinical overview of sorafenib, a multikinase inhibitor that targets
both raf and VEGF and PDGF receptor tyrosine kinase signaling. Molecular
Cancer Therapeutics, 7(10), 3129-3140. doi:10.1158/1535-7163.MCT-08-0013;
10.1158/1535-7163.MCT-08-0013
62. Wood, E. R., Truesdale, A. T., McDonald, O. B., Yuan, D., Hassell, A.,
Dickerson, S. H., et al. (2004). A unique structure for epidermal growth factor
receptor bound to GW572016 (lapatinib): Relationships among protein

75

conformation, inhibitor off-rate, and receptor activity in tumor cells. Cancer
Research, 64(18), 6652-6659. doi:10.1158/0008-5472.CAN-04-1168
63. Yacoub, A., Hamed, H., Emdad, L., Dos Santos, W., Gupta, P., Broaddus, W. C.,
et al. (2008). MDA-7/IL-24 plus radiation enhance survival in animals with
intracranial primary human GBM tumors. Cancer Biology & Therapy, 7(6), 917933.
64. Yang, F., Brown, C., Buettner, R., Hedvat, M., Starr, R., Scuto, A., et al. (2010).
Sorafenib induces growth arrest and apoptosis of human glioblastoma cells
through the dephosphorylation of signal transducers and activators of
transcription 3. Molecular Cancer Therapeutics, 9(4), 953-962.
doi:10.1158/1535-7163.MCT-09-0947; 10.1158/1535-7163.MCT-09-0947
65. Youle, R. J., & Strasser, A. (2008). The BCL-2 protein family: Opposing
activities that mediate cell death. Nature Reviews.Molecular Cell Biology, 9(1),
47-59. doi:10.1038/nrm2308
66. Yu, J., Zhang, L., Hwang, P. M., Kinzler, K. W., & Vogelstein, B. (2001). PUMA
induces the rapid apoptosis of colorectal cancer cells. Molecular Cell, 7(3), 673682.

76

